CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: May-22-15
Credit Expiration Date: May-22-16


Alice Ma, MD
Clinical Associate Professor of Medicine
Department of Medicine
Division of Hematology-Oncology
University of North Carolina School of Medicine
Chapel Hill, NC

Credit Hours



Online Presentation

Program Description

NOTE: This activity was presented as a live visiting faculty grand rounds series beginning on February 6, 2015. Participants who received credit for attending any of the live presentations are not eligible to receive credit for this online release.

Acquired hemophilia (AH) is a rare but potentially life-threatening bleeding disorder caused by the development of autoantibodies directed against plasma coagulation factors. Despite the fact that AH is a “potentially curable disorder” that can be associated with an excellent prognosis under the right circumstances, the AH-associated mortality rate is as high as 20% to 25%, suggesting that clinicians are not optimally diagnosing and managing patients with this disorder. This activity seeks to educate hospital clinicians on strategies for timely and accurate diagnosis and optimal therapeutic selection in patients with AH.

Program Developer/Facilitator

This activity is jointly provided by Global Education Group and MCM Education

Target Audience

Hematologists, surgeons, OB/GYNs, emergency medicine physicians, internists, hospitalists, and their cross-functional teams, and other hospital clinicians involved in the treatment and care of patients with AH.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Discuss methods of diagnosing AH through laboratory testing and clinical evaluation.
  2. Review available guideline recommendations for treatment and management of AH.
  3. Summarize the current state of optimal AH care based on recently published medical literature.
  4. List investigational agents and treatment strategies that may be incorporated into future standards of AH care.


Alice Ma, MD, discloses that she has served as a consultant/independent contractor for Bayer and Novo Nordisk.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN: Nothing to disclose
Amanda Glazar, PhD: Nothing to disclose
Andrea Funk: Nothing to disclose
Lillian McVey (MCM Education editor): Nothing to disclose

Credit Statements

ACCREDITATION STATEMENT: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group and MCM Education. Global Education Group is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT: Global Education Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit
In order to obtain credit, participants must review the activity in its entirety and complete the post test and evaluation.

Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or

Commercial Support Statements

This activity is supported through an independent education grant from Baxter Healthcare.

Certificate Fee



Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and MCM Education do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu